Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

GLP-1 Insurance Coverage: What Wegovy, Zepbound, Ozempic, and Mounjaro Actually Cost You

By
Published Updated Last reviewed
12 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Approved for weight management / Wegovy injection and tablets, Saxenda and generic liraglutide, Zepbound, Foundayo [2][3][4][5]
  • Diabetes labels only / Ozempic, Rybelsus, Victoza, Trulicity, Byetta, Mounjaro, Soliqua, Xultophy [2][3][4][5][6][7]
  • Separate products, separate labels / Ozempic and Wegovy have different labeled uses; so do Mounjaro and Zepbound [2][6][4][7]
  • Insurer practice reported in 2024 / Many insurers would not cover semaglutide solely for weight management; some diabetes prescriptions needed prior authorization documenting type 2 diabetes [8]
  • Access across income groups / A 2023 review linked lower GLP-1 uptake in disadvantaged groups partly to suboptimal insurance coverage [10]
  • Compounded versions / Not FDA approved; not reviewed for safety, effectiveness or quality [9]

What each of these four drugs is approved for

Wegovy injection is approved to reduce excess body weight and maintain weight loss in adults and children 12 and older with obesity and in adults with overweight plus at least one weight-related condition, to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and for noncirrhotic MASH with moderate to advanced fibrosis; Wegovy tablets are approved for weight reduction and cardiovascular risk reduction in adults [2]. Zepbound is the tirzepatide product labeled for weight management and sleep apnea [4], while Mounjaro is the tirzepatide product labeled for type 2 diabetes [7].

Ozempic is labeled for type 2 diabetes, with cardiovascular and kidney outcome indications in type 2 diabetes, and its label does not include weight management [6]. The other products grouped with this class, including Rybelsus, Victoza, Trulicity, Byetta, Soliqua and Xultophy, are labeled for type 2 diabetes rather than weight management [2][3][4][5].

What published reports say about coverage

A 2024 clinical commentary, drawing on published literature and clinical experience, reported that clinicians started prescribing Ozempic and dulaglutide for weight loss even though neither is FDA approved for that use, and that this off-label use may have increased because many insurers will not cover semaglutide solely for weight management [8]. It described insurance coverage for weight management as sparse, and said insurers were requiring a prior authorization proving an FDA-approved type 2 diabetes diagnosis for diabetes prescriptions [8].

A 2023 review found that uptake of GLP-1 receptor agonists is lower among people who live in socioeconomically disadvantaged areas, have low income or education, or belong to racial or ethnic minorities, and it listed suboptimal health insurance coverage among the contributing factors [10].

What the labels do and do not cover

The FDA labels state each product's approved uses [2][3][4][5][6][7]. They do not address formularies, prior authorization criteria, Medicare Part D, Medicaid or savings programs, which are set by individual plans and programs.

Compounded semaglutide and tirzepatide

Compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed [9].

Frequently asked questions

Which of these four drugs is FDA approved for weight loss?
Wegovy is approved for weight reduction in adults and children 12 and older with obesity, and Zepbound is the tirzepatide product labeled for weight management and sleep apnea [2][4]. Ozempic and Mounjaro are labeled for type 2 diabetes; Ozempic also carries cardiovascular and kidney outcome indications in type 2 diabetes [6][7].
How does the labeled use affect insurance coverage?
A 2024 clinical commentary reported that many insurers would not cover semaglutide solely for weight management and described prior authorization requirements that document an FDA-approved type 2 diabetes diagnosis for some diabetes prescriptions [8]. Formulary rules for each product are set by the individual plan.
Are compounded semaglutide and tirzepatide FDA approved?
No. Compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [9].

References

  1. Hernandez I, Sullivan SD. Net prices of new antiobesity medications. Obesity (Silver Spring). 2024;32(3):472-475. Net prices of new antiobesity medications
  2. U.S. National Library of Medicine, DailyMed. Wegovy injection and tablets prescribing information. Wegovy injection and tablets label
  3. U.S. National Library of Medicine, DailyMed. Saxenda injection (liraglutide) prescribing information. Saxenda injection (liraglutide) label
  4. U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
  5. U.S. National Library of Medicine, DailyMed. Foundayo (orforglipron) tablets prescribing information. Foundayo (orforglipron) tablets label
  6. U.S. National Library of Medicine, DailyMed. Ozempic injection prescribing information. Ozempic injection label
  7. U.S. National Library of Medicine, DailyMed. Mounjaro injection (tirzepatide) prescribing information. Mounjaro injection (tirzepatide) label
  8. Powell J, Taylor J. Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management. Clin Ther. 2024;46(3):289-292. Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management
  9. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
  10. Karagiannis T, Bekiari E, Tsapas A. Socioeconomic aspects of incretin-based therapy. Diabetologia. 2023;66(10):1859-1868. Socioeconomic aspects of incretin-based therapy
  11. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
  12. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on Bulks List | FDA. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on Bulks List | FDA
Evidence overview for GLP-1 Insurance Coverage: What Wegovy, Zepbound, Ozempic, and Mounjaro Actually Cost You